| Years Since | Diagnosis | 0 to <5 | 5 to <10 | 10 to <15 | 15 to <20 | 20 to <25 | 25 to <30 | 0 to $<20^{\text {e }}$ | 0 to $<37^{\text {e }}$ | $>=37^{9}$ | Complete ${ }^{\text {h }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Race | Sex |  |  |  |  |  |  |  |  |  |  |
| All Races ${ }^{\text {b }}$ | Both Sexes | 34,042 | 5,941 | 2,492 | 1,380 | 789 | 430 | 44,240 | 45,432 | 270 | 45,702 |
|  | Males | 17,628 | 2,644 | 1,241 | 479 | 395 | 107 | 22,190 | 22,666 | 117 | 22,783 |
|  | Females | 16,414 | 3,297 | 1,251 | 901 | 394 | 323 | 22,050 | 22,766 | 153 | 22,919 |
| White ${ }^{\text {b }}$ | Both Sexes | 27,956 | 5,052 | 1,946 | 1,019 | 597 | 332 | 36,320 | 37,195 | 220 | 37,415 |
|  | Males | 14,674 | 2,268 | 1,083 | 345 | 336 | 74 | 18,561 | 18,920 | 104 | 19,024 |
|  | Females | 13,282 | 2,784 | 863 | 674 | 261 | 258 | 17,759 | 18,275 | 116 | 18,391 |
| Black ${ }^{\text {b }}$ | Both Sexes | 4,327 | 581 | 345 | 199 | 153 | 60 | 5,476 | 5,722 | 127 | 5,849 |
|  | Males | 2,084 | 261 | 93 | 42 | 52 | 26 | 2,481 | 2,581 | 53 | 2,634 |
|  | Females | 2,243 | 320 | 252 | 157 | 101 | 34 | 2,995 | 3,141 | 74 | 3,215 |
| Asian/ | Both Sexes | 1,335 | 239 | 121 | + | + | + | 1,755 | + | + | + |
| Pacific | Males | 614 | 109 | 41 | + | + | + | 789 | + | + | + |
| Islander ${ }^{\text {c }}$ | Females | 721 | 130 | 80 | + | + | + | 966 | + | + | + |
| Hispanic ${ }^{\text {d }}$ | Both Sexes | 2,386 | 473 | 203 | + | + | + | 3,216 | + | + | + |
|  | Males | 1,247 | 155 | 83 | + | + | + | 1,518 | + | + | + |
|  | Females | 1,139 | 318 | 120 | + | + | + | 1,698 | + | + | + |

Estimated prevalence percent ${ }^{a}$ on January 1, 2012, of the SEER ${ }^{\text {c }}$ population diagnosed in the previous 20 years By Age at Prevalence, Race/Ethnicity and Sex

a US 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER registries and $1 / 1 / 2012$
US 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER registries and $1 / 2011$ and 2012 population estimates from the US Bureau of the Census.
b c d Prevalence was calculated using the First Malignant Primary Only for a person. $\quad$ Statistics based on (b) SEER 9 Areas (c) SEER 11 Areas and Rural Georgia (d) NHIA for Hispanic for SEER 11 Areas and - Rural Georgia.
e Maximum limited-duration prevalence: 37 years for 1975-2012 SEER 9 data; 20 years for $1992-2012$ SEER 11 data
f (used to calculate prevalence for Hispanics and Asian Pacific Islanders).
ghi Percentages are age-adjusted to the 2000 US Standard population (19 age groups - Census P25-1130) by 5-year age groups Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <37 and >=37. (i) Age-specific compieteness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
$+\quad$ Not available.

